Grifols reinforces its liquidity position to EUR 1,700 million

- The company upsizes its multicurrency revolving credit facility from USD 500 million to USD 1,000 million in order to further reinforce its already-solid liquidity position, which totaled EUR 1,200 million on March 31, 2020.

- Amid the current COVID-19 context, Grifols once again adopts a proactive approach by taking the necessary measures to bolster its robust liquidity position.

Barcelona, May 7, 2020.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) today signed an upsize of its multicurrency revolving credit facility with the banks that participated in the refinancing process finalized in November 2019. Following this transaction, the company’s liquidity position increases from USD 500 million to USD 1,000 million with maturity in November 2025.

The expansion of the revolving credit line – which continues to be undrawn and will not increase the company’s indebtedness – will enable Grifols to reinforce its liquidity position, which currently stands at EUR 1,700 million compared to the EUR 1,200 million reported in the first quarter of 2020.

In light of the COVID-19 pandemic, Grifols is once again adopting a proactive approach by taking all necessary measures to further bolster its already-solid liquidity position.

The terms and conditions of this new transaction are in line with those signed in November 2019.

In November 2019, Grifols concluded its debt refinancing process, enabling it to optimize its financial structure and extend average maturities to more than seven years. The process also provided greater flexibility in covenant conditions (cov-lite). The company does not face significant maturity repayments or down payments until 2025.

As a company, Grifols is highly equipped to address the demands of the current situation and remains firmly committed to its long-term growth strategy.
About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols’ economic impact in its core countries of operation was 8.5 billion euros. The company also generated 148,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group
GRIFOLS

has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.